BCL2A1 and CCL18 Are Predictive Biomarkers of Cisplatin Chemotherapy and Immunotherapy in Colon Cancer Patients

Background: Cisplatin enhances the antitumor T cell response, and the combination of PD-L1 blockade produces a synergistic therapeutic effect. However, the clinical correlation between cisplatin and immunotherapy in colon cancer (CC) is unknown. Methods: Using the “pRRophetic” package, we calculated...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Taohua, Liu, Xiangzheng, Zuo, Shuai, Zhu, Jing, Li, Jichang, Liu, Yucun, Chen, Shanwen, Wang, Pengyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898943/
https://www.ncbi.nlm.nih.gov/pubmed/35265629
http://dx.doi.org/10.3389/fcell.2021.799278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898943/
https://www.ncbi.nlm.nih.gov/pubmed/35265629
http://dx.doi.org/10.3389/fcell.2021.799278

Ejemplares similares